Omega-3 polyunsaturated fatty acids/ubiquinone Disease Interactions

Cases of recurrent atrial fibrillation (AF) or flutter have been reported with the use of omega-3 fatty acids in patients with a symptomatic paroxysmal AF or persistent AF. This condition is more apparent within the first 2 to 3 months after the initiation of therapy. Therapy with these agents should be administered cautiously in patients with cardiac conduction disorders.

Increases in alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) levels have been observed in patients receiving omega-3 fatty acids. Therapy with omega-3 fatty acid preparations should be administered cautiously in patients with hepatic impairment. Serum liver enzyme levels should be monitored periodically.